<DOC>
	<DOCNO>NCT01210560</DOCNO>
	<brief_summary>To establish pharmacokinetics ( PK ) , pharmacodynamics ( PD ) , adverse event ( AE ) profile tolvaptan administer modified-release ( MR ) formulation ADPKD subject . The goal trial two-fold : 1 . To directly compare immediate release ( IR ) MR formulation 2 . To determine dose range dose regimen MR ( dose finding )</brief_summary>
	<brief_title>Dose-finding Study New Tolvaptan Formulation Subjects With ADPKD</brief_title>
	<detailed_description>Group 1 12 subject enrol 3-period , randomize , crossover compare multiple dos 90-30 mg split-dose tolvaptan IR formulation , 120 mg daily ( QD ) dose tolvaptan MR formulation , , incomplete block randomization , multiple dos either 20 mg QD , 60 mg QD , 20 mg twice daily ( BID ) tolvaptan MR formulation . All dose regimen administer 7 day . Placebo dose administer order mask QD v BID treatment . Group 2 12 subject enrol 3-period , randomize , crossover compare multiple oral dos tolvaptan MR formulation administer 7 day 20 mg QD , 60 mg QD , 20 mg BID . Placebo capsule administer order mask QD v BID treatment . Subjects in-clinic assessment 12 day obtain 24-hour PK PD data . Subjects visit clinic afternoon Day -1 morning Day 1 . They return end dosing period similar inpatient period ( ie , afternoon Day 6 morning Day 8 , afternoon Day 13 morning Day 15 , afternoon Day 20 morning Day 22 ) . Except first dose period dose take clinic last day regimen afternoon Days 6 , 13 20 , dose take subject outpatient .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney , Autosomal Dominant</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>Subjects ( male female ) surgically sterile ( ie , undergone hysterectomy ) use contraception agree remain abstinent Subjects age 18 50 , inclusive Subjects body mass index 19 35 kg/m2 ( inclusive ) Subjects diagnosis ADPKD modify Ravine criterion Subjects must good health determine medical history , physical examination , ECG , serum/urine biochemistry , hematology , serology test Subjects ability provide write , informed consent prior initiation trialrelated procedure , ability , opinion principle investigator , comply requirement trial Subjects expect able complete dose period assessment within 42 ( +2 ) day dose Day 1 Subjects use diuretic within 14 day prior check Day 1 Subjects incontinence , overactive bladder , urinary retention ( eg , benign prostatic hyperplasia ) Subjects ( male female ) nocturia/urgency ( outside 2 4 time awaken per night expect ADPKD patient ) screen Subjects liver disease , liver function abnormality serology expect ADPKD cystic liver disease baseline Subjects clinically significant abnormality past medical history , Screening physical examination , investigator 's sponsor 's opinion may place volunteer risk interfere outcome variable include absorption , distribution , metabolism , excretion drug . This include , limited , history concurrent cardiac , hepatic , renal , neurologic , endocrine , gastrointestinal , respiratory , hematologic , immunologic disease Subjects history drug and/or alcohol abuse within 2 year prior screen Subjects history test positive screening hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( antiHCV ) , and/or human immunodeficiency virus ( HIV ) Subjects clinically significant allergic reaction tolvaptan chemically related structure benzazepines ( eg , benzazepril , conivaptan , fenoldopam mesylate mirtazapine ) Subjects take investigational drug within 30 day precede trial entry Subjects history significant bleeding hemorrhagic tendency Subjects history difficulty donate blood Subjects donate blood plasma within 30 day prior dose Subjects consume alcohol and/or food beverage contain methylxanthines , grapefruit , grapefruit juice , Seville oranges , Seville orange juice within 72 hour prior Day 1 dose Subjects take CYP3A4 inhibitor , exception amiodarone , take within 30 day dose ( eg , amprenavir , atorvastatin , aprepitant , chloramphenicol [ eye drop ] , cimetidine , clarithromycin , clotrimazole [ use orally ] , danazol , delavirdine , diltiazem , erythromycin , fluconazole , fluvoxamine , indinavir , isoniazid , itraconazole , josamycin , ketoconazole , nelfinavir , nefazadone , quinupristin/dalfopristin , ritonavir , saquinavir , troleandomycin , verapamil ) Subjects take CYP3A4 inducer take within 7 day dose ( eg , rifampin , St. Johns Wort ) Subjects history serious mental disorder Subjects previous exposure tolvaptan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Kidney Disease</keyword>
	<keyword>Polycystic Kidney Disease</keyword>
</DOC>